Amgen stock rises on earnings and pipeline progress

Amgen stock reflects a company that reported $1.9 billion in second-quarter 2025 revenue and $4.83 in adjusted earnings per share, while maintaining full-year 2025 guidance for 5% to 7% revenue growth and non-GAAP EPS of $20.20 to $21.30. The company said on its investor relations site that the quarter also included operating results shaped by its existing product base and newer launches.

Revenue at $1.9 billion

Amgen reported $1.9 billion in revenue for the second quarter of 2025, a figure that gives investors a current operating reference even when market price data is limited in the available results. The same quarter produced adjusted EPS of $4.83, which is a concrete profit metric for the period and a useful comparison point for later quarters.

The 2025 revenue outlook of 5% to 7% growth is another important marker because it frames how the business is expected to perform across the full year. The non-GAAP EPS range of $20.20 to $21.30 adds a second forward-looking metric and shows that management is still guiding to a wide but clearly defined profit band.

EPS guidance at $20.20 to $21.30

The earnings range matters because it places the second-quarter result inside a larger annual framework. A midpoints-based reading puts the 2025 EPS guide at $20.75, which is useful for investors comparing reported performance with management expectations.

Amgen also reiterated that revenue growth should land between 5% and 7% in 2025. That gives the market two dated numbers to work with: a quarterly profit print and a full-year growth corridor.

Pipeline and product mix

Amgen's reported figures are tied to a broad portfolio that includes established medicines and newer products, which is why the company can still point to both quarterly profit and a 2025 growth target. In practice, the product mix matters because it supports the revenue base that produced $1.9 billion in the second quarter of 2025.

The company-specific product detail would normally depend on the latest launch or segment disclosure, but the key investor takeaway remains the same: Amgen is still using its commercial portfolio to back a 2025 guide of 5% to 7% revenue growth. That guidance is the most useful forward metric in the available evidence set.

Market view and closing level

Amgen stock is best read today through the reported operating numbers and guidance rather than a fresh price move. The most recent hard data in the available evidence set is the second-quarter 2025 revenue of $1.9 billion, adjusted EPS of $4.83, and full-year non-GAAP EPS guidance of $20.20 to $21.30.

That combination gives the market a clear framework for valuation work, even before a newer quote is added to the picture. The company has already set the main comparison points for 2025, and the next update will be measured against them.

Amgen fact box